US 10,869,858 B2 · Therapeutic agent for amyotrophic disorders

Abstract

It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R3 represents OH.

Claims1

Dependent claims

A method for treating amyotrophic lateral sclerosis, comprising administering, to a patient in need of treatment for amyotrophic lateral sclerosis, a compound selected from the following formulas

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

15/769,793Filed 24 Jun 2016

Priority

JP 2015-21328029 Oct 2015

Published

US 2019/0054066 A121 Feb 2019

Granted

22 Dec 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/405
Indoles, e.g. pindolol: indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 31/192
Carboxylic acids, e.g. valproic acid: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/454
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 21/00
Drugs for disorders of the muscular or neuromuscular system

Therapeutic agent for amyotrophic disorders

Life of this patent

Therapeutic agent for amyotrophic disorders

Life of this patent

Abstract

Claims1